BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 25553994)

  • 61. Association of capsular types with carbapenem resistance, disease severity, and mortality in
    Hsieh YC; Wang SH; Chen YY; Lin TL; Shie SS; Huang CT; Lee CH; Chen YC; Quyen TLT; Pan YJ
    Emerg Microbes Infect; 2020 Dec; 9(1):2094-2104. PubMed ID: 32912064
    [No Abstract]   [Full Text] [Related]  

  • 62. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
    Chuang YC; Cheng CY; Sheng WH; Sun HY; Wang JT; Chen YC; Chang SC
    BMC Infect Dis; 2014 Feb; 14():102. PubMed ID: 24564226
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii.
    Chusri S; Sakarunchai I; Kositpantawong N; Panthuwong S; Santimaleeworagun W; Pattharachayakul S; Singkhamanan K; Doi Y
    Int J Antimicrob Agents; 2018 Apr; 51(4):646-650. PubMed ID: 29241820
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
    Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
    Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia.
    Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multicentre study of risk factors for mortality in patients with Acinetobacter bacteraemia receiving colistin treatment.
    Lee YT; Sun JR; Wang YC; Chiu CH; Kuo SC; Chen TL; ; Yang YS
    Int J Antimicrob Agents; 2020 Jun; 55(6):105956. PubMed ID: 32278810
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.
    Ozbek B; Otük G
    Int J Antimicrob Agents; 2010 Aug; 36(2):191-2. PubMed ID: 20537868
    [No Abstract]   [Full Text] [Related]  

  • 68. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
    Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
    Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand.
    Anunnatsiri S; Tonsawan P
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure.
    Wang YC; Lee YT; Yang YS; Chen CT; Chiu CH; Yin T; Kuo SC; Chen TL; Lin JC; Wang FD; Fung CP; Chang FY
    Clin Microbiol Infect; 2015 Aug; 21(8):758-64. PubMed ID: 25980356
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical outcomes of patients infected with carbapenem-resistant Acinetobacter baumannii treated with single or combination antibiotic therapy.
    Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
    J Med Assoc Thai; 2011 Jul; 94(7):863-70. PubMed ID: 21774295
    [TBL] [Abstract][Full Text] [Related]  

  • 73. "Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia.
    Poulakou G; Bassetti M; Tsiodras S
    Crit Care Med; 2015 Oct; 43(10):e470-1. PubMed ID: 26376274
    [No Abstract]   [Full Text] [Related]  

  • 74. Clinical experience with tigecycline in the treatment of carbapenem-resistant Acinetobacter infections.
    Metan G; Alp E; Yildiz O; Percin D; Aygen B; Sumerkan B
    J Chemother; 2010 Apr; 22(2):110-4. PubMed ID: 20435570
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Carbapenem-resistant Acinetobacter baumannii Bacteremia in Liver Transplant Recipients.
    Kim YJ; Kim SI; Lee YD; Choi HJ; Choi JY; Yoon SK; You YK; Kim DG
    Transplant Proc; 2018 May; 50(4):1132-1135. PubMed ID: 29731080
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit.
    Young LS; Sabel AL; Price CS
    Infect Control Hosp Epidemiol; 2007 Nov; 28(11):1247-54. PubMed ID: 17926275
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
    Russo A; Gullì SP; D'Avino A; Borrazzo C; Carannante N; Dezza FC; Covino S; Polistina G; Fiorentino G; Trecarichi EM; Mastroianni CM; Torti C; Oliva A
    Int J Antimicrob Agents; 2024 Jul; 64(1):107190. PubMed ID: 38697579
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii.
    Chusri S; Singkhamanan K; Wanitsuwan W; Suphasynth Y; Kositpantawong N; Panthuwong S; Doi Y
    J Infect Chemother; 2019 Sep; 25(9):681-686. PubMed ID: 31003954
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia.
    Park SY; Lee EJ; Kim T; Yu SN; Park KH; Lee MS; Park SY; Jeon MH; Kim TH; Choo EJ
    Int J Antimicrob Agents; 2018 Mar; 51(3):407-412. PubMed ID: 29122697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.